Hubert Czerniak TV - Fakty i mity o witaminie D3! Lepiej usiądźcie - ta wiedza Was zaskoczy! #D3

Czerniak frames D3 monotherapy as a recipe for disaster. He cites his own clinical rescue of a woman with acute renal failure from D3 alone; adding high-dose K2 normalized her creatinine and averted dialysis. He stresses that if someone runs a study giving only D3 without A, E, K2, they will find harm and shorten life — but with the full suite, survival rises. This aligns with his broader view that the fat-soluble vitamin complex (A, D, E, K2) is a functional unit depleted in modern food. He refers back to the historical context: food used to contain 10x the fat-soluble vitamins, so the need for exogenous K2 was lower. Now, supplementing D3 in isolation creates an imbalance akin to revving an unprotected engine. He also mentions that even in Finland's cohort showing 88% T1D reduction, they used D3 as part of a broader nutritional context, not a single pill.

Czerniak shows images comparing a healthy mineral/vitamin tissue profile with one where serum D3 is high but tissue D3 is zero. He suggests that this can explain why some people fail to improve despite 'optimal' blood levels. He advises viewers to personally verify supplement quality using such tests, rather than trusting brands. The test appears to measure sweat or interstitial fluid parameters painlessly. He also notes that contamination with heavy metals can be assessed. The protocol is essentially a quality-control step: if tissue values don't rise, switch product.

Czerniak contrasts this 60 ng/mL target with official guidelines (600-400 IU/day aiming for 20-30 ng/mL) and the Copenhagen J-curve 'optimum' of 20-24 ng/mL. He points out that the Robert Koch Institute found 58% of Germans between 17-79 had levels below 20 ng/mL, and the Frankfurt University survey showed 45.8% below 10 ng/mL among medical staff. He emphasizes that the 30 ng/mL threshold is where serious diseases start appearing, and that many studies show inverse correlations between D3 levels and mortality from heart disease, cancer, and respiratory illness. The 60 ng/mL figure comes from an unnamed epidemiologist with decades of experience. He also references Professor Reinhold's safety data: only one documented human overdose at extremes of 1.7 million IU/day for 7 months, which supports the wide therapeutic window.

Czerniak connects the modern phobia of sun exposure to pharmaceutical interests. He points out that historically, hospital wards treated psoriasis with quartz lamps (UV phototherapy) — essentially artificial sunlight — and that going to a solarium can replicate this. He notes that sunlight and D3 also improve mood and mental health, which is critical since psoriasis patients often become suicidal. He cites his colleague's case where raising D3 (likely through a combination of sun and oral supplementation) resolved severe psoriasis. The broader message is that the sun is not the enemy; the epidemic of low D3 is partly due to sun avoidance messages.

He outlines a scenario: a patient with high vitamin D levels and rising creatinine is told their kidneys are failing because of D3. He urges that before accepting that, you must ask for monoclonal protein testing. The logic is that multiple myeloma is a plasma cell cancer that damages kidneys and is common enough that it should be ruled out. He implies that the anti-D3 bias leads physicians to prematurely blame the supplement rather than investigate the root cause. This is part of his larger argument that the medical establishment finds D3 a convenient scapegoat.

Czerniak highlights that deficiency in pregnant mammals causes subtle but irreversible brain changes in offspring. He presents a dosing ladder: 6400 IU/day is the threshold where breastmilk begins to show increased D3, while 100,000 IU/day results in 8000 IU/L, approximating the level an infant might get from historical supplementation. This is a sharp departure from the standard 400-600 IU pregnancy recommendation. He ties this to the earlier historical data where newborns were given 2000 IU/day directly and the dramatic reduction in type 1 diabetes (88% in Finland). The implication is that prenatal and early-life D3 sufficiency could prevent autoimmune and neurological epidemics.

Czerniak systematically dismantles the study's methodology. First, the paper itself admits it cannot establish causality and calls for further research, yet its findings are presented as evidence of harm. He lists cardinal flaws: the sample lacks any stratification by age, so we don't know if deaths occurred in 50-year-olds or 80-year-olds; no information on comorbidities that triggered supplementation; no data on starting vitamin D levels, target levels, or why the person aimed for a given level; and no disease-course comparison between supplemented vs non-supplemented groups with the same illness. Most critically, the J-shape is exactly what you'd expect when a population of sick patients discovers D3 and raises their levels dramatically — those with the highest levels are the most ill, hence their elevated mortality. Meanwhile, people hovering around 20-30 ng/mL are often undiagnosed or early-stage, so their mortality is lower. He contrasts the 50-60 nmol/L 'optimum' with the well-established threshold of 30 ng/mL (75 nmol/L) below which chronic inflammatory and malignant diseases begin. For Czerniak, the paper is a 'laughingstock' and 'not science but a distorting mirror'.

He presents a case where a patient had 57% serum level (quite decent) but after certain supplements, laboratory blood showed approximately 300 ng/mL while the tissue reading was zero. He likens this to diabetes — sugar overflowing in veins but tissues starving. He admits he doesn't know why this happens, calling on academic professors with PhD students to investigate. The implication is that not all supplements are bioavailable or that some individuals have a metabolic block preventing cellular entry, making blood tests alone potentially misleading. The remedy he suggests is to switch supplements and verify with both blood and tissue tests until tissue numbers rise.

Czerniak stresses that giving D3 alone is like adding a turbo and direct nitrous injection to an engine without reinforcing the crankshaft and transmission — you're asking for a breakdown. The case involved a young woman who read a little, didn't know the full picture, took only vitamin D3, reached several hundred ng/mL, and her creatinine spiked, landing her in hospital with the team preparing for dialysis. When Czerniak added high-dose K2, the kidneys recovered fully. He generalizes: 'If someone does an experiment and gives vitamin D3 alone, I can already say they will live shorter' — but with the full complement (A, E, K2), survival increases.

He explains that after 25-hydroxylation in the liver, the pre-hormone travels to all tissues. In active tissues — pancreas, bone, intestinal epithelium, brain, adrenal, breast, colon, prostate — there is abundant 1-alpha hydroxylase that locally produces the active hormone. This local production regulates gene expression and cellular function independently of renal output. This discovery means that serum 1,25(OH)2D3 does not reflect tissue-level activity, and it explains why high 25(OH)D3 (the substrate) is necessary for the tissues to draw on. He also notes the safety valve: 24-hydroxylase deactivates excess, and the body excretes catabolites, so toxicity is rare unless the enzyme is defective (1 in a million).

Czerniak recounts that early in his career, a colleague had psoriasis so severe it deformed his nails, with plaques that caused his spouse to be repulsed. He used only vitamin D3 to raise blood levels to around 200 ng/mL. The psoriasis vanished entirely. He underscores that psoriasis is not just a skin condition but a psychiatric one — many patients commit suicide because of how they look. He points out that historically hospitals used quartz lamps (UV phototherapy) for psoriasis, and that sunlight or even solarium can be used. He also lists exacerbating factors: alcohol, beta-blockers, and AIDS. The D3 approach here harnesses the same VDR-driven keratinocyte maturation pathway that slows epidermal turnover.